Use of CEA and CA15-3 to predict axillary lymph node metastasis in patients with breast cancer

Journal of Cancer

Volumn 7, Issue 1, 2016, Pages 37-41

  Wu, San Gang ^a   He, Zhen Yu ^b   Ren, Hong Yue ^a   Yang, Li Chao ^c   Sun, Jia Yuan ^b   Li, Feng Yan ^b   Guo, Ling ^b   Lin, Huan Xin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Axillary lymph node metastases; Breast cancer; CA15 3; CEA

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD LEVEL; BREAST CANCER; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 84953849666     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13090     Document Type: Article

References (25)

1. Kuehn T, Klauss W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000;64(3):275-86.
2. Kwan W, Jackson J, Weir LM, et al. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002;20(20):4242-8.
3. Erickson VS, Pearson ML, Ganz PA, et al. Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93(2):96-111.
4. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients withsentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252(3):426-32; discussion 432-3.
5. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: arandomized clinical trial. JAMA 2011;305(6):569-75.
6. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24(9):2206-23.
7. Wu SG, He ZY, Zhou J, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast 2014;23(1):88-93.
8. Lee JS, Park S, Park JM, et al. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 2013;24(5):1225-31.
9. Molina R, Auge JM, Farrus B, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem 2010;56(7):1148-57.
10. Park BW, Oh JW, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008;19(4):675-81.
11. Li FY, Wu SG, Zhou J, et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One 2014;9(2):e87264.
12. Ugras S, Stempel M, Patil S, et al. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph nodeinvolvement. Ann Surg Oncol 2014;21(12):3780-6.
13. Gangi A, Mirocha J, Leong T, et al. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases. Ann Surg Oncol 2014;21(13):4098-103.
14. Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in asingle institution. Cancer. 2005;103(3):492-500.
15. Greer LT, Rosman M, Charles Mylander W, et al. A prediction model for the presence of axillary lymph node involvement in women with invasive breast cancer: afocus on older women. Breast J 2014;20(2):147-53.
16. Crabb SJ, Cheang MC, Leung S, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primarybreast cancer. Clin Breast Cancer 2008;8(3):249-56.
17. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98(2):413-23.
18. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57(2):327-34.
19. Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers for management of breast cancer patients. Biomed Res Int 2013;2013:685641.
20. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010;411(23-24):1869-74.
21. Kim MJ, Park BW, Lim JB, et al. Axillary lymph node metastasis: CA-15-3 and carcinoembryonic antigen concentrations in fine-needle aspiratesfor preoperative diagnosis in patients with breast cancer. Radiology 2010;254(3):691-7.
22. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment andfollow-up. Ann Oncol 2012;23 Suppl 7:vii11-9.
23. Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 2005;26(6):281-93.
24. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(7):961-5.
25. Ramsey SD, Henry NL, Gralow JR, et al. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol 2015;33(2):149-55.